Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review
Frontiers in Endocrinology · 2026
DOI: 10.3389/fendo.2026.1817448 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Ji Yong Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chonnam National University Medical School, Hwasun, Republic of Korea. Hauptthemen laut MEDLINE: Adenocarcinoma, Follicular, Bone Neoplasms, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hyperfunctioning distant metastases from differentiated thyroid carcinoma (DTC) are rare but increasingly reported. We report hormone-producing lung and bone metastases from an HRAS-mutated high-grade differentiated thyroid carcinoma (HGDTC) originating from follicular thyroid carcinoma (FTC), with a brief literature review. The metastases showed a marked response to radioactive iodine (RAI). Patient findings A 68-year-old woman presented with an enlarging thyroid nodule and multiple pulmonary nodules after starting antithyroid therapy for Graves’ disease. Histopathology confirmed HGDTC arising from FTC, and next-generation sequencing identified an HRAS Gln61Arg mutation. Thyrotoxicosis persisted after total thyroidectomy. A post-therapeutic whole-body radioiodine scan demonstrated iodine-avid pulmonary nodules and a left iliac bone lesion, consistent with hyperfunctioning distant metastases. Summary After two RAI treatments, thyroid function shifted from hyperthyroidism to hypothyroidism, and follow-up chest computed tomography showed a significant reduction in pulmonary metastatic lesions.
Conclusions
Hyperfunctioning distant metastases from DTC present diagnostic and therapeutic challenges. This case highlights the consideration of functioning metastases in persistent post-thyroidectomy thyrotoxicosis and demonstrates the potential effectiveness of RAI therapy when metastatic lesions retain iodine avidity. Oncogenic mutations such as HRAS may contribute to the pathophysiology of hormone-producing metastases and provide insights into tumor differentiation and therapeutic responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chonnam National University Medical School, Hwasun, Republic of Korea.
- Department of Nuclear Medicine, Chonnam National University Medical School, Hwasun, Republic of Korea.
- Department of Pathology, Chonnam National University Medical School, Hwasun, Republic of Korea.
Zitieren
APA
Park, J. Y., Yoo, S. W., Kim, S. S., Hong, A. R., Yoon, J. H., Kim, H. K., & Kang, H. C. (2026). Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1817448
Vancouver
Park JY, Yoo SW, Kim SS, Hong AR, Yoon JH, Kim HK, et al. Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1817448
BibTeX
@article{Park2026,
author = {Park, Ji Yong and Yoo, Su Woong and Kim, Sung Sun and Hong, A Ram and Yoon, Jee Hee and Kim, Hee Kyung and Kang, Ho-Cheol},
title = {Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review},
journal = {Frontiers in Endocrinology},
year = {2026},
doi = {10.3389/fendo.2026.1817448}
}
EUVIMED